Anavex Life Financials

AVXL Stock  USD 9.03  0.01  0.11%   
Based on the measurements of operating efficiency obtained from Anavex Life's historical financial statements, Anavex Life Sciences may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Anavex Life's Cash And Short Term Investments are quite stable compared to the past year. Common Stock Total Equity is expected to rise to about 94.1 K this year, although the value of Retained Earnings are projected to rise to (250.6 M). Key indicators impacting Anavex Life's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio11.6411.09
Sufficiently Up
Slightly volatile
Investors should never underestimate Anavex Life's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Anavex Life's cash flow, debt, and profitability to make informed and accurate decisions about investing in Anavex Life Sciences.

Net Income

(40.6 Million)

  
Understanding current and past Anavex Life Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Anavex Life's financial statements are interrelated, with each one affecting the others. For example, an increase in Anavex Life's assets may result in an increase in income on the income statement.

Anavex Life Stock Summary

Anavex Life competes with Cassava Sciences, INmune Bio, Biovie, Cognition Therapeutics, and Annovis Bio. Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company was incorporated in 2004 and is headquartered in New York, New York. Anavex Lf operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS0327973006
CUSIP032797300 032797102
LocationNew York; U.S.A
Business Address630 5th Avenue,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.anavex.com
Phone844 689 3939
CurrencyUSD - US Dollar

Anavex Life Key Financial Ratios

Anavex Life Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets34.5M161.6M152.7M154.4M177.5M186.4M
Other Current Liab3.3M5.6M6.4M8.2M9.4M9.9M
Net Debt(29.2M)(152.1M)(149.2M)(151.0M)(135.9M)(129.1M)
Retained Earnings(159.7M)(197.6M)(245.6M)(293.1M)(263.8M)(250.6M)
Cash29.2M152.1M149.2M151.0M173.7M182.4M
Total Liab7.3M10.8M10.2M12.5M14.4M15.1M
Total Current Assets34.5M161.6M152.7M154.4M177.5M186.4M
Common Stock62.0K75.9K77.9K82K94.3K99.0K
Accounts Payable4.0M4.7M3.8M4.3M5.0M5.2M
Other Current Assets443.8K371.9K354K653K751.0K496.3K
Net Receivables4.8M9.1M3.2M2.7M3.1M2.1M
Net Tangible Assets27.2M150.8M142.5M141.9M163.1M171.3M
Capital Surpluse153.6M186.9M348.3M388.0M446.2M468.5M
Net Invested Capital27.2M150.8M142.5M141.9M163.1M82.9M
Net Working Capital27.2M150.8M142.5M141.9M163.1M82.9M
Capital Stock62.0K75.9K77.9K82K94.3K72.7K

Anavex Life Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense4.8M4.0M947.0K964K1.1M1.3M
Operating Income(30.8M)(41.9M)(54.4M)(47.5M)(42.7M)(40.6M)
Ebit(57.8M)(79.1M)(47.6M)(47.5M)(42.7M)(40.6M)
Ebitda(31.1M)(41.7M)(50.9M)(47.5M)(42.7M)(40.6M)
Net Income(26.3M)(37.9M)(48.0M)(47.5M)(42.7M)(40.6M)
Income Tax Expense22.7K267.6K358.5K(7K)(6.3K)(6.0K)
Income Before Tax(26.3M)(37.6M)(47.6M)(47.5M)(42.7M)(40.6M)
Research Development25.2M33.0M37.9M43.7M50.3M52.8M
Interest Income180.0K26.3K947.0K6.5M7.5M7.9M
Tax Provision22.7K267.6K358.5K7K8.1K7.6K
Net Interest Income180.0K26.3K947.0K5.6M6.4M6.7M

Anavex Life Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash7.1M122.9M(2.9M)1.9M2.1M2.0M
Free Cash Flow(21.3M)(30.4M)(24.2M)(27.8M)(25.0M)(23.8M)
Net Income(26.3M)(37.9M)(48.0M)(47.5M)(42.8M)(40.6M)
End Period Cash Flow29.2M152.1M149.2M151.0M173.7M182.4M
Other Non Cash Items6.6M11.8M13.3M845K971.8K923.2K
Change To Netincome4.9M8.2M18.4M17.2M19.8M20.8M
Change To Inventory2.2M4.3M(5.9M)(484K)(435.6K)(413.8K)

Anavex Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Anavex Life's current stock value. Our valuation model uses many indicators to compare Anavex Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Anavex Life competition to find correlations between indicators driving Anavex Life's intrinsic value. More Info.
Anavex Life Sciences is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . At this time, Anavex Life's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Anavex Life by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Anavex Life Sciences Systematic Risk

Anavex Life's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Anavex Life volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Anavex Life Sciences correlated with the market. If Beta is less than 0 Anavex Life generally moves in the opposite direction as compared to the market. If Anavex Life Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Anavex Life Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Anavex Life is generally in the same direction as the market. If Beta > 1 Anavex Life moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Anavex Life Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Anavex Life's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Anavex Life growth as a starting point in their analysis.

Price Earnings To Growth Ratio

4.12

At this time, Anavex Life's Price Earnings To Growth Ratio is quite stable compared to the past year.

Anavex Life November 27, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Anavex Life help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Anavex Life Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Anavex Life Sciences based on widely used predictive technical indicators. In general, we focus on analyzing Anavex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Anavex Life's daily price indicators and compare them against related drivers.
When determining whether Anavex Life Sciences is a strong investment it is important to analyze Anavex Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Anavex Life's future performance. For an informed investment choice regarding Anavex Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anavex Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.51)
Return On Assets
(0.20)
Return On Equity
(0.30)
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.